The prevalence and direct costs of multiple sclerosis therapy in Poland from 2008 to 2016

Jacyna, Andrzej; Śliwczyński, Andrzej; Stachurski, Jarosław; Zbylut, Monika; Gałek, Justyna; Eliasz, Piotr; Łabenda, Andrzej; Gajewski, Krzysztof; Kasińska, Beata; Majkut, Gabriela; Janaszek, Katarzyna; Wiktorzak, Katarzyna; Dziełak, Dariusz; Wierzba, Waldemar; Kozierkiewicz, Adam; Jaworska, Urszula; Skrzypek, Mariusz; Gałązka-Sobotka, Małgorzata; Jantarski, Konrad; Brzozowska, Melania; Marczak, Michał; Orlewska, Ewa

doi:10.5114/ms.2018.74817

Cited by 2 publications

(2 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The National Health Fund (NHF) in Poland tracks all medical conditions treated within the public healthcare system, including all medical procedures and treatments of 43 459 patients with MS (in 2016). 10 The main drivers for total MS expenditures accounting for 68% were costs of DMD therapy, 10 although the access to this treatment in Poland still belongs to the lowest in Europe: in 2013 the percentage of Polish patients with MS who receive DMDs was 13%, 11 and in 2016 it was 25%. 10,12 Most of the established MS treatments have become available in Poland.…”

Section: Introductionmentioning

confidence: 99%

“…10 The main drivers for total MS expenditures accounting for 68% were costs of DMD therapy, 10 although the access to this treatment in Poland still belongs to the lowest in Europe: in 2013 the percentage of Polish patients with MS who receive DMDs was 13%, 11 and in 2016 it was 25%. 10,12 Most of the established MS treatments have become available in Poland. However, certain reimbursement restrictions, such as limitations of the number of treated patients or limitations of treatment duration, still occur and limit access to therapy.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Impact of Immunoablation and Autologous Hematopoietic Stem Cell Transplantation on Treatment Cost of Multiple Sclerosis: Real-World Nationwide Study

Orlewska

Bogusz

Podlecka-Piętowska

et al. 2021

Value in Health Regional Issues

Self Cite

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Impact of Immunoablation and Autologous Hematopoietic Stem Cell Transplantation on Treatment Cost of Multiple Sclerosis: Real-World Nationwide Study

Orlewska

Bogusz

Podlecka-Piętowska

et al. 2021

Value in Health Regional Issues

Self Cite

View full text Add to dashboard Cite

Determinants of developing a pilot of coordinated care model for patients with multiple sclerosis in Poland

Wiktorzak¹,

Szafraniec-Byryło²,

Jaworska³

et al. 2019

MSP

View full text Add to dashboard Cite

Background: Multiple sclerosis is a chronic and highly debilitating disease with very high economic and social consequences. Designing changes to improve the functioning of the healthcare model primarily requires learning about the needs of beneficiaries. Aim of the study: The purpose of our study is the results’ description and summary of conclusions of the research conducted in the past years. These results are currently being used for the construction of a coordinated care model for MS patients. Material and methods: One questionnaire survey addressed to MS patients, carried out between 01.12.2013 and 01.02.2014 and the second one addressed to Polish and European medical professionals, carried out between 01.09.2016 and 04.10.2016 performed in 51 European centers and 2 branches of the Turkish Association of patients with MS. Results: In the first survey 84.4% patients declared that during the illness they received mental support mostly from their family: 48.5% received it from physicians; 42.1% from a nurse. 64.8% of the respondents declared that they received no support from social organizations and 77.6% received no support from religious organizations. According to the results of the survey for healthcare professionals in Poland and Europe, in 54.9% of the European institutions and in 22.4% of the Polish institutions, dedicated IT systems are used for processing MS patients’ data. Among institutions using IT, 52.9% of the European and 10.1% of the Polish ones keep the patient’s entire documentation, as well as a patient satisfaction survey, in an IT system. Conclusions: Based on our studies described above, the patients’ needs, resources and capabilities seem to indicate that the scale of system inefficiencies is such that remodeling care for this well-defined group of patients is justified and feasible.

show abstract

The prevalence and direct costs of multiple sclerosis therapy in Poland from 2008 to 2016

Cited by 2 publications

References 5 publications

Impact of Immunoablation and Autologous Hematopoietic Stem Cell Transplantation on Treatment Cost of Multiple Sclerosis: Real-World Nationwide Study

Impact of Immunoablation and Autologous Hematopoietic Stem Cell Transplantation on Treatment Cost of Multiple Sclerosis: Real-World Nationwide Study

Determinants of developing a pilot of coordinated care model for patients with multiple sclerosis in Poland

Contact Info

Product

Resources

About